We are pioneers in the field of complement-mediated rare diseases. Our scientists are focused on discovering novel therapies for rare diseases in which the complement alternative pathway is a key driver of pathogenesis.

Unlike C5 blockers in the complement space, we focus on therapies that can intervene upstream in the complement system, selectively targeting the underlying pathway of each disease in question. One drug can target many diseases. We are continuously motivated by the needs of patients as we discover unique therapies for rare diseases. Every rare disease is unique, but their treatment may be similar to others if they fall under complement-mediated diseases to be treated by the same drug. Such opportunities are extremely exciting for innovators and drug developers. In essence, we would deliver one drug treating many diseases.

Ablenio has a robust product-driven technology capable of producing a proprietary pipeline of novel therapeutic monoclonal antibodies to diagnose and treat complement-mediated diseases.

Fundamental to our current and future success is a multi-disciplinary approach through the discovery and development processes. With a talented and experienced team, Ablenio is poised to continue on its path to develop life-changing therapies for patients with unmet needs.

Our lead product candidate:

NM8074, is a first-in-class, anti-Bb antibody that selectively targets the alternative pathway of Complement . This drug is currently completing a Phase I trial in healthy volunteers for a multitude of rare diseases similar to those mentioned above. The well differentiated mechanism of action is expected to make this monoclonal a unique treatment option.

We are excited to move towards clinical validation of our drug and welcome collaborators and partners who share our vision.